J&J Pays $2.2B Upfront for Ollin's Vabysmo Rival OLN324
J&J will acquire Ollin Biosciences for $2.2B upfront plus $1.1B in milestones, gaining VEGF/Ang2 inhibitor OLN324, now in four Phase 3 trials against Eylea and Lucentis.
TAG V-6006 · 574 words on the filing

Summary of findings
- J&J acquires Ollin Biosciences for $2.2B upfront plus up to $1.1B in milestones
- Blackstone Life Sciences commits $750M to Phase 3 testing of OLN324
- Four Phase 3 trials underway: two in wet AMD, two in diabetic macular edema, all against Lucentis or Eylea
- OLN324 targets VEGF and Ang2, the same pathway as Roche's Vabysmo, approved in 2022
- Ollin's second asset, Tepezza rival OLN102, is preclinical
Johnson & Johnson will pay $2.2 billion upfront — and up to $1.1 billion more in milestones — to acquire Ollin Biosciences, a startup whose lead eye drug OLN324 could challenge Roche's blockbuster Vabysmo. That's a total potential price near $3.3 billion for a company that launched just last year.
Blackstone Life Sciences is putting $750 million behind Phase 3 testing of OLN324 in wet age-related macular degeneration (the leading cause of vision loss in older adults) and diabetic macular edema. In exchange, Blackstone becomes eligible for milestone payments and royalties if the drug reaches market.
Why is J&J paying this much?
The deal reshapes an ophthalmology business built mostly on hardware. J&J's eye franchise today runs on contact lenses, medical devices and surgical equipment; prescription medicines for eye conditions have been a side bet, limited to dabbling such as its partnership with gene therapy developer MeiraGTx.
OLN324 gives J&J a direct entry into retinal pharmacology. The drug originated at Shanghai-based Innovent Biologics and, like Vabysmo, hits two proteins — VEGF and Ang2 — that drive progression of age-related macular degeneration. Ollin has claimed the molecule may be more potent and longer-lasting than established treatments.
The commercial prize is real. Vabysmo became a blockbuster after its initial approval in 2022 and has taken share from Regeneron's widely used Eylea. J&J wants a seat at that table.
What do the trials look like?
Phase 3 entries on a federal clinical trial database show four late-stage studies: two in wet AMD and two in diabetic macular edema. All four compare OLN324 head-to-head against either Lucentis or Eylea.
The evidence so far rests on a Phase 1b study that supported the drug's potential. How much better it actually is remains the open question.
"OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," said Kip Connor, J&J's Ophthalmology Disease Area Stronghold Leader, in a statement. "The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients."
What are analysts saying?
RBC Capital Markets analyst Trung Huynh called the deal a "logical strategic fit" given J&J's established eye-care presence. But he flagged two concerns.
First, differentiation. With Phase 1b data only, it's unclear how distinct OLN324 is in what he described as a "very competitive and crowded space." Second, price. The amount J&J paid "appears high" against the valuations of other competitors in the field, he wrote.
The skepticism has grounds. Multiple dual VEGF/Ang2 inhibitors are already fighting for retina share, and head-to-head wins against Eylea and Lucentis won't settle the durability question overnight.
What else came with the deal?
Ollin, backed by Arch Venture Partners and TCGX among others, launched last year with two medicines licensed from China-based developers, both aimed at well-known targets. The second asset travels with the acquisition: OLN102, a potential competitor to Horizon's thyroid eye disease drug Tepezza, currently in preclinical development.
So J&J buys one Phase 3 asset, one preclinical option, and a development partner in Blackstone sharing the Phase 3 bill. The bet is that potency and dosing convenience can carve share from entrenched rivals.
via BioPharma Dive (Source)
More from Daniel Okafor
Show full bio
Correspondent covering technology and product news in global pharmaceutical industry at PharmInsider.
11 articles
Linked filings
- K-8919
- K-1191
- K-8037
- K-1653
- V-5496